secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001558370-24-010223
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS reports positive Phase 1a data for PMN310 in Alzheimer's
---------------------------------------------------------------

- PMN310 well-tolerated across four SAD cohorts (2.5-20 mg/kg); no treatment-emergent SAEs.
- CSF levels dose-proportional at days 3 and 29; lowest dose >100-fold molar excess over expected oligomers.
- CSF half-life ~25 days, supportive of monthly dosing.
- Company plans to initiate Phase 1b in Alzheimer's patients in H2 2024.
- Full dataset to be presented at a medical meeting in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024010223/0001558370-24-010223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024010223/pmn-20240726x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer